Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Gastric carcinoma: an evolutionary scenario.]

Fabio Gelsomino1, Andrea Spallanzani1, Ferdinando De Vita2

  • 1Dipartimento di Oncologia ed Ematologia, Azienda Ospedaliero-Universitaria Policlinico di Modena, Università di Modena e Reggio Emilia.

Recenti Progressi in Medicina
|April 12, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Complete and Persistent Response to Immunotherapy in Highly Pretreated MSS TMB-High Pancreatic Adenocarcinoma: A Case Report and Literature Review.

International journal of molecular sciences·2026
Same author

Genome-wide SNP-based Profiling of Loss of Heterozygosity Reveals Distinct Molecular Subgroup-specific Patterns in Gastrointestinal Stromal Tumors (GIST).

Laboratory investigation; a journal of technical methods and pathology·2026
Same author

Preparing real-world data through common data model harmonization of cancer patient records in the COMNet platform at the Modena Oncology Center.

Frontiers in digital health·2026
Same author

Real-world presentation and outcomes of gastroenteropancreatic neuroendocrine neoplasms in Italy: findings from the nationwide Itanet prospective database.

The Lancet regional health. Europe·2026
Same author

Second-line chemotherapy after gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: comparative outcomes and AI-guided treatment selection.

The oncologist·2026
Same author

Nivolumab plus ipilimumab for hepatocellular carcinoma: a game-changer?

Expert opinion on biological therapy·2026

Gastric cancer, though declining, remains a major European killer. Advances in molecular classification and targeted therapies like trastuzumab and ramucirumab offer personalized treatment and a continuum of care, alongside crucial nutritional support.

Area of Science:

  • Oncology
  • Gastroenterology
  • Molecular Biology

Background:

  • Gastric cancer is a significant cause of cancer death in Europe, despite decreasing incidence.
  • Traditional Lauren classification categorizes gastric adenocarcinoma into intestinal and diffuse subtypes.
  • Emerging molecular classifications offer insights into carcinogenesis and personalized treatment strategies.

Purpose of the Study:

  • To review recent advancements in gastric cancer treatment and care.
  • To highlight the impact of molecular classifications on personalized medicine.
  • To discuss the evolution of targeted therapies and supportive care in gastric cancer management.

Main Methods:

  • Literature review of recent clinical trials and retrospective/prospective studies.

Related Experiment Videos

  • Analysis of molecular classifications and their clinical implications.
  • Evaluation of targeted therapies (trastuzumab, ramucirumab) and nutritional support.

    • Main Results:

    • Trastuzumab introduced targeted therapy in first-line treatment.
    • Ramucirumab established second-line therapy, creating a "continuum of care".
    • Nutritional counseling and support are confirmed as vital in all disease stages.

    Conclusions:

    • Personalized treatment approaches are becoming standard in gastric cancer care.
    • Targeted therapies and a continuum of care model are improving patient outcomes.
    • Integrated nutritional support is essential for managing gastric cancer patients effectively.